Cargando…
Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
SIMPLE SUMMARY: We present the results of a prospective trial of systemic chemoimmunotherapy for primary CNS lymphoma including the intra-arterial administration of methotrexate and carboplatin with blood–brain barrier disruption. The safety, response rates, and survival outcomes were favorable. Pre...
Autores principales: | Kuitunen, Hanne K., Rönkä, Aino L. K., Sonkajärvi, Eila M., Isokangas, Juha-Matti, Pyörälä, Marja, Palosaari, Kari A. A., Jokimäki, Anna S., Partanen, Anu E., Littow, Harri J., Vakkala, Merja A., Jantunen, Esa J., Huttunen, Mirja E., Marin, Katja J., Aromaa-Häyhä, Annikki M. K., Auvinen, Päivi K., Selander, Tuomas, Puhakka, Inka K., Kuittinen, Outi M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953868/ https://www.ncbi.nlm.nih.gov/pubmed/36831682 http://dx.doi.org/10.3390/cancers15041341 |
Ejemplares similares
-
Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis
por: Puhakka, Inka, et al.
Publicado: (2022) -
Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma
por: Partanen, Anu, et al.
Publicado: (2021) -
Physiological instability is linked to mortality in primary central nervous system lymphoma: A case–control fMRI study
por: Poltojainen, Valter, et al.
Publicado: (2022) -
Real-time monitoring of human blood-brain barrier disruption
por: Kiviniemi, Vesa, et al.
Publicado: (2017) -
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
por: Harmanen, Minna, et al.
Publicado: (2023)